INTRODUCTION AND OBJECTIVES: Activating transcriptional factor 2 (ATF2) is normally activated via its phosphorylation in response to phospho-ERK (p-ERK) signals, leading to promotion of tumor outgrowth demonstrated in several types of malignancies. However, biological significance of ATF2 in bladder cancer remains poorly understood. This study aimed to determine the functional role of ATF2 in urothelial carcinogenesis as well as cancer progression in relation to androgen receptor (AR) signaling.
METHODS: First, we immunohistochemically stained for ATF2, phospho-ATF2 (p-ATF2), and p-ERK in 129 bladder cancer and paired non-neoplastic bladder tissue specimens. Second, in human bladder cancer lines, we assessed the effects of ATF2 knockdown via shRNA virus infection on cell proliferation, migration, and invasion. Third, in human normal urothelial SVHUC cells with exposure to a chemical carcinogen 3-methylcholanthrene (MCA), we assessed the effects of ATF2 knockdown on neoplastic transformation.
RESULTS: ATF2/p-ATF2/p-ERK were positive in 84%/32%/ 26% of bladder tumors, which were significantly elevated, compared with non-neoplastic urothelial tissues [64% (P[0.001)/2% (P<0.001)/ 10% (P[0.008)], respectively. Multivariate analysis showed that moderate/strong ATF2 expression and p-ATF2 positivity were independent predictors for recurrence of low grade tumors (HR[2.956, P[0.045) and cancer-specific mortality of muscleinvasive tumors (HR[5.317, P[0.012) , respectively. In both neoplastic and non-neoplastic urothelial cells, the expression levels of AR were associated with those of p-ATF2. Dihydrotestosterone treatment in AR(þ) bladder cancer cells also induced the expression of p-ATF2/p-ERK and nuclear translocation/transcriptional activity of ATF2. ATF2 knockdown in AR(þ) bladder cancer lines resulted in significant decreases in cell viability/migration/invasion, as well as tumor growth in xenograft-bearing mice, and significant increases in apoptosis and G0/G1 cell cycle phase. Finally, ATF2 knockdown in SVHUC cells stably expressing AR resulted in significant inhibition in MCA-induced neoplastic transformation and the expression of several oncogenes. By contrast, ATF2 modulation did not exhibit significant inhibitory effects in AR(-) bladder cancer or SVHUC lines.
CONCLUSIONS: ATF2 activity appears to correlate with bladder cancer outgrowth in the presence of an activated AR. Accordingly, ATF2 inhibition, together with AR inactivation, has the potential of being an effective chemopreventive and/or therapeutic approach for urothelial carcinoma.
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MP51-11 EPIGENETIC REGULATION OF FORKHEAD BOX A1 IN ADVANCED BLADDER CANCER
Jenna Buckwalter*, Vasty Osei Amponsa, Lauren Shuman, Vonn Walter, Joshua Warrick, Hershey, PA; Xue-Ru Wu, New York, NY; Jay Raman, David DeGraff, Hershey, PA INTRODUCTION AND OBJECTIVES: Bladder cancer (BC) is the second most common urologic malignancy and has notable molecular and morphologic heterogeneity that is associated with clinical outcome. Transcription factor forkhead box A1 (FOXA1) is required for maintenance of urothelial differentiation, and FOXA1 loss is associated with the development of basal-squamous BC which responds differentially to therapeutic intervention. Thus, manipulating FOXA1 expression to control subtype specification is an attractive concept. The aim of this study was to determine the mechanism(s) responsible for loss of FOXA1 expression in BC.
METHODS: Computational analysis of publically available data through the TCGA bladder study was used to examine the relationship between FOXA1 mutational status, copy number, methylation status and gene expression. In tandem, the UCSC genome browser was used to identify CpG islands in the FOXA1 promoter as potential sites of promoter methylation. A PCR-based system for detecting methylated CpG islands was used to determine the methylation status of FOXA1 in a panel of human BC cell lines.
RESULTS: Analysis of RNA-seq data confirms decreased FOXA1 expression is common in human BC and associated with the basal-squamous molecular subtype. However, FOXA1 expression was not correlated with mutational status and/or copy number alterations, suggesting a role for epigenetic silencing. Three CpG islands were identified in the FOXA1 promoter and gene body, which include islands 99, 123, and 143. Statistical analysis of TCGA DNA methylation data identified methylation at CpG island 99 is significantly associated with reduced FOXA1 expression (p<0.0009; Wilcoxon rank Sum), while island 143 was unmethylated. We next extended our methylation analysis for CpG islands to human BC cell lines with defined molecular subtypes. CpG island 99 was methylated specifically in basal BC cell lines which fail to express FOXA1, while CpG island 143 was unmethylated. Although CpG island 123 was methylated in all ten cell lines, we failed to detect any association between methylation status and FOXA1 expression or molecular subtype.
CONCLUSIONS: Our data indicates that unlike mutational status or copy number, methylation patterns of specific CpG islands are significant contributors to the regulation of FOXA1 expression in human BC. Specifically, methylation of CpG island 99 is found in advanced disease and human BC cell lines. Our study additionally shows the importance of examining promoter methylation in association with gene expression to determine the functional consequences of epigenetic alterations. INTRODUCTION AND OBJECTIVES: Advanced bladder cancer exhibits a unique degree of morphologic and molecular intratumoral heterogeneity. While tumor heterogeneity in bladder cancer is associated with clinical outcome and therapeutic response, the mechanism(s) responsible for emergence of this phenotype are largely unknown. We previously identified decreased expression of the urothelial differentiation factor FOXA1 within bladder cancers exhibiting heterogeneity in the form of squamous differentiation. In addition, PTEN inactivation was recently associated with "squamous-like" cancers of the bladder and other organs. These observations suggest a potentially cooperative role for FOXA1 and PTEN loss in the development of bladder cancer and/or associated tumor heterogeneity. Therefore, we initiated a study focused on identifying mechanisms underlying reduced PTEN and FOXA1 expression in bladder cancer, as well as their functional contribution to disease.
METHODS: Gene expression and copy number alteration analysis was conducted using human data through The Cancer Genome Atlas Bladder project. In addition, to determine the functional consequence of reduced PTEN and FOXA1 expression in disease, we conditionally ablated Foxa1 and/or Pten in the urothelium of mice. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e727
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